Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGE-A3 and NY-ESO-1 Peptide Vaccines in Multiple Myeloma
NCT00090493Phase 3Completed
- Sponsor
- University of Arkansas
- Start
- Jun 2004
- Primary completion
- Jul 2007
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of MAGE-3 peptide and ny-eso-1 peptide in multiple myeloma (MM), sponsored by University of Arkansas. Primary endpoint: The Number of Participants Experiencing a Response to the Peptide Vaccines. Started Jun 2004; status: completed.
02
Drugs
MAGE-3 peptideny-eso-1 peptide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00090493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00090493.